Novel microneutralization assay for HCMV using automated data collection and analysis

Journal of Immunological Methods

Volumn 322, Issue 1-2, 2007, Pages 82-93

  Abai, Anna Maria ^a   Smith, Larry R ^a   Wloch, Mary K ^a  

^a VICAL INC   (United States)

Author keywords

ELISPOT analyzer; Human cytomegalovirus; Microneutralization assay

Indexed keywords

VIRUS DNA;

ANIMAL CELL; ARTICLE; AUTOMATION; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOMEGALOVIRUS; DATA ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOPEROXIDASE STAINING; MICRONEUTRALIZATION ASSAY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SIGNAL DETECTION; VIRUS NEUTRALIZATION;

BLOOD; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MINIATURIZATION; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY;

HUMAN HERPESVIRUS 5;

EID: 34147104047     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2007.02.001     Document Type: Article

References (32)

1. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., Dellamonica P., Best A.M., Zahradnik J., Pincus S., Berencsi K., Cox W.I., and Gyulai Z. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine. J. Infect. Dis. 180 (1999) 843
2. Alpert G., Mazeron M.C., Colimon R., and Plotkin S. Rapid detection of human cytomegalovirus in the urine of humans. J. Infect. Dis. 152 (1985) 631
3. Andreoni M., Faircloth M., Vugler L., and Britt W.J. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23 (1989) 157
4. Andreoni K.A., Wang X., Huang S.M., and Huang E.S. Human cytomegalovirus hyperimmune globulin not only neutralizes HCMV infectivity, but also inhibits HCMV-induced intracellular NF-kappaB, Sp1, and PI3-K signaling pathways. J. Med. Virol. 67 (2002) 33
5. Britt W.J., Vugler L., Butfiloski E.J., and Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64 (1990) 1079
6. Cheong S.C., Clement N., Velu T., and Brandenburger A. A novel method for the titration of recombinant virus stocks by ELISPOT assay. J. Virol. Methods 109 (2003) 119
7. Chou S.W., and Scott K.M. Rapid quantitation of cytomegalovirus and assay of neutralizing antibody by using monoclonal antibody to the major immediate-early viral protein. J. Clin. Microbiol. 26 (1988) 504
8. Demmler G.J., Istas A., Easley K.A., and Kovacs A. Results of a quality assurance program for detection of cytomegalovirus infection in the pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus infection study. J. Clin. Microbiol. 38 (2000) 3942
9. Eizuru Y., Ueno I., and Minamishima Y. Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement. J. Clin. Microbiol. 26 (1988) 1881
10. Gleaves C.A., and Meyers J.D. Comparison of MRC-5 and HFF cells for the identification of cytomegalovirus in centrifugation culture. Diagn. Microbiol. Infect. Dis. 6 (1987) 179
11. Gleaves C.A., Smith T.F., Shuster E.A., and Pearson G.R. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19 (1984) 917
12. Gonczol E., Ianacone J., Furlini G., Ho W., and Plotkin S.A. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J. Infect. Dis. 159 (1989) 851
13. Gonczol E., deTaisne C., Hirka G., Berencsi K., Lin W.C., Paoletti E., and Plotkin S. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9 (1991) 631
14. Griffiths P.D., Panjwani D.D., Stirk P.R., Ball M.G., Ganczakowski M., Blacklock H.A., and Prentice H.G. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet 2 (1984) 1242
15. Han D.P., Kim H.G., Kim Y.B., Poon L.L., and Cho M.W. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 326 (2004) 140
16. Klein M., Schoppel K., Amvrossiadis N., and Mach M. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol. 73 (1999) 878
17. Lantto J., Fletcher J.M., and Ohlin M. A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B. J. Gen. Virol. 83 (2001)
18. Lewis R.B., Matzke D.S., Albrecht T.B., and Pollard R.B. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay. Rev. Infect. Dis. 8 Suppl 4 (1986) S434
19. Lockridge K.M., Sequar G., Zhou S.S., Yue Y., Mandell C.P., and Barry P.A. Pathogenesis of experimental rhesus cytomegalovirus infection. J. Virol. 73 (1999) 9576
20. Marshall G.S., Rabalais G.P., Stout G.G., and Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 165 (1992) 381
21. Mitchell D.K., Holmes S.J., Burke R.L., Duliege A.M., and Adler S.P. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21 (2002) 133
22. Nejatollahi F., Hodgetts S.J., Vallely P.J., and Burnie J.P. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol. Med. Microbiol. 34 (2002) 237
23. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., and Burke R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180 (1999) 970
24. Pepperl S., Munster J., Mach M., Harris J.R., and Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 74 (2000) 6132
25. Schmidt N.J., Dennis J., and Lennette E.H. Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells. J. Clin. Microbiol. 4 (1976) 61
26. Schoppel K., Hassfurther E., Britt W., Ohlin M., Borrebaeck C.A., and Mach M. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216 (1996) 133
27. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., and Evans T. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccines 1 (2005) 16
28. Swenson P.D., and Kaplan M.H. Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J. Clin. Microbiol. 21 (1985) 669
29. Wang Z., Mo C., Kemble G., and Duke G. Development of an efficient fluorescence-based microneutralization assay using recombinant human cytomegalovirus strains expressing green fluorescent protein. J. Virol. Methods 120 (2004) 207
30. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., Longmate J., Ellenhorn J.D., Siliciano R.F., Buck C., Britt W.J., and Diamond D.J. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104 (2004) 847
31. Wloch, M., manuscript in preparation.
32. Wloch, M., unpublished data.